Head-To-Head Contrast: Autolus Therapeutics (NASDAQ:AUTL) & Windtree Therapeutics (NASDAQ:WINT)

Autolus Therapeutics (NASDAQ:AUTLGet Rating) and Windtree Therapeutics (NASDAQ:WINTGet Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for Autolus Therapeutics and Windtree Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Autolus Therapeutics 0 0 4 0 3.00
Windtree Therapeutics 0 0 1 0 3.00

Autolus Therapeutics presently has a consensus price target of $13.67, suggesting a potential upside of 476.65%. Windtree Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 1,354.55%. Given Windtree Therapeutics’ higher probable upside, analysts plainly believe Windtree Therapeutics is more favorable than Autolus Therapeutics.

Profitability

This table compares Autolus Therapeutics and Windtree Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Autolus Therapeutics -6,551.06% -52.00% -42.38%
Windtree Therapeutics N/A -134.71% -80.04%

Insider & Institutional Ownership

61.5% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 11.4% of Windtree Therapeutics shares are owned by institutional investors. 16.1% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Autolus Therapeutics and Windtree Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Autolus Therapeutics $2.33 million 92.47 -$142.10 million ($1.86) -1.27
Windtree Therapeutics $200,000.00 80.87 -$67.64 million ($2.48) -0.22

Windtree Therapeutics has lower revenue, but higher earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Autolus Therapeutics has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500.

Summary

Autolus Therapeutics beats Windtree Therapeutics on 8 of the 13 factors compared between the two stocks.

Autolus Therapeutics Company Profile (Get Rating)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Windtree Therapeutics Company Profile (Get Rating)

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.